HCFA Policy Change Allows Partial Reimbursement For Amgen's Epogen
Executive Summary
The Health Care Financing Administration will allow partial reimbursement of Amgen's Epogen (erythropoietin) at doses that cause patients to exceed hematocrit levels of 36%.